Although additional in vivo studies and clinical trials are required to explore the efficacy and safety, the cytotoxic effect of EphA2 inhibition in combination with paclitaxel may provide a novel treatment strategy for patients with advanced NPC. The gene discussed is EPHA2; the disease is nasopharyngeal carcinoma.